Stomach Neoplasms Clinical Trial
Official title:
An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy
Purpose: To assess the utility of a new medical device that monitors a patient's breathing
during medical procedures in which a patient is sedated, but not mechanically ventilated. In
minor procedures, such as endoscopy (where the doctor examines a patient's digestive tract by
a TV camera inserted through the mouth), patients do not require general anesthesia, in which
a machine would take over their breathing while they are unconscious for surgery. However,
during endoscopic procedures it is sometimes difficult for the anesthesiologist to monitor
the patient's breathing—specifically, to monitor changes in breathing patterns and the
adequacy of breathing. In endoscopy procedures, the room is darkened, and the patient's mouth
is generally occupied by the endoscope. While the anesthesiologist can listen to the
patient's breathing sounds with a stethoscope, this type of monitoring can only be done
periodically, and there is limited ability to gauge the adequacy of ventilation. This study
will use the ExSpiron Respiratory Volume Monitor (RVM), which measures non-invasive minute
ventilation (MV), tidal volume (TV) and respiratory rate (RR), in patients undergoing an
endoscopic procedure to provide additional information regarding the effects of clinical
interventions such as drug administrations or airway maneuvers on the patient's respiratory
status.
For patients who give informed consent, study participation means that they will have a
PadSet consisting of 3 electrodes applied to the chest. Another component, a nasal cannula (a
thin clear plastic tube that goes under the nose) will give patients supplemental oxygen, and
is standard of care for endoscopy at UVM Medical Center. Patients will then be asked to
breathe in and out of a portable spirometer (breath meter) for 30 seconds up to five times.
This data will be compared to data recorded by the monitor to confirm that the monitor is
recording accurately. The procedure will then go forward in the normal fashion. Patients will
be randomly placed into one of two groups. In the first group during the procedure, the
anesthesiologist will not be able to see the numbers (MV, TV, and RR) displayed screen of the
monitor, so the data will not be used to guide the patient's clinical care. In the second
group, the anesthesiologist will be able to see the RVM measurements of MV, TV, and RR to
evaluate the effect of the interventions. Monitoring for both groups will continue in the
recovery room, until discharge.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | December 2016 |
Est. primary completion date | June 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria: - Subjects undergoing upper gastrointestinal endoscopy Exclusion Criteria: - Patients with a history of thoracotomy with resection of lung tissue - Patients with a history of severe chronic obstructive pulmonary disease (defined as an inability to climb a flight of stairs or FEV1/VC of less than 30% of predicted) - BMI greater than 43. |
Country | Name | City | State |
---|---|---|---|
United States | University of Vermont Medical Center | Burlington | Vermont |
Lead Sponsor | Collaborator |
---|---|
Donald Mathews | Respiratory Motion, Inc. |
United States,
Bhananker SM, Posner KL, Cheney FW, Caplan RA, Lee LA, Domino KB. Injury and liability associated with monitored anesthesia care: a closed claims analysis. Anesthesiology. 2006 Feb;104(2):228-34. — View Citation
Freeman J, Lalli M, Yocum N, Panasyuk A, Panasyuk S, and Lew R, 328: Non-invasive Monitoring of Tidal Volume and Minute Ventilation in Non-intubated Patients. Critical Care Medicine, 2011. 39(12): p. 88 10.1097/01.ccm.0000408627.24229.88.
Holley K, Mathews D, Freeman J, Brayanov J, Schapiro H. The Use of a Respiratory Volume Monitor to Assess Ventilation Before & After Airway Maneuvers during Upper Endoscopy. Poster Presentation, American Society of Anesthesiologists, October 2013, San Francisco, CA
LaPierre CD, Johnson KB, Randall BR, White JL, Egan TD. An exploration of remifentanil-propofol combinations that lead to a loss of response to esophageal instrumentation, a loss of responsiveness, and/or onset of intolerable ventilatory depression. Anesth Analg. 2011 Sep;113(3):490-9. doi: 10.1213/ANE.0b013e318210fc45. Epub 2011 Mar 17. — View Citation
Metzner J, Posner KL, Domino KB. The risk and safety of anesthesia at remote locations: the US closed claims analysis. Curr Opin Anaesthesiol. 2009 Aug;22(4):502-8. doi: 10.1097/ACO.0b013e32832dba50. — View Citation
Voscopoulos C, Brayanov J, Ladd D, Lalli M, Panasyuk A, Freeman J. Special article: evaluation of a novel noninvasive respiration monitor providing continuous measurement of minute ventilation in ambulatory subjects in a variety of clinical scenarios. Anesth Analg. 2013 Jul;117(1):91-100. doi: 10.1213/ANE.0b013e3182918098. Epub 2013 Jun 3. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Average minute ventilation in patients cared for using the ExSpiron Respiratory Variation Monitor (RVM) compared to patients with routine monitoring in patients undergoing upper gastrointestinal endoscopy | Duration of procedure: Approximately 60 minutes | ||
Secondary | Incidence of airway maneuvers required to maintain ventilation in each group | Duration of procedure: Approximately 60 minutes | ||
Secondary | Effectiveness of airway maneuvers in each group (change in minute ventilation) | Duration of procedure: Approximately 60 minutes | ||
Secondary | Time required to return to baseline ventilator parameters following the procedure. | Duration of procedure and time in the recovery room: Approximately 120 minutes | ||
Secondary | Incidence of hypopnea in each group | Duration of procedure: Approximately 60 minutes | ||
Secondary | Average oxygen saturation between the two groups | Duration of procedure: Approximately 60 minutes | ||
Secondary | Percentage of time with oxygenation less than 90% between the two groups | Duration of procedure: Approximately 60 minutes | ||
Secondary | The ability of respiratory parameters with capnography to assess states of hypoventilation between the two groups | Duration of procedure: Approximately 60 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01950572 -
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
|
||
Recruiting |
NCT05161572 -
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
|
Phase 2 | |
Not yet recruiting |
NCT04351867 -
A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer
|
Phase 3 | |
Recruiting |
NCT02887612 -
ctDNA for Prediction of Relapse in Gastric Cancer
|
||
Active, not recruiting |
NCT02930291 -
The Effect of Preoperative Inflammation-based Scores on Postoperative Morbidity and Mortality for Laparoscopic Gastrectomy
|
||
Completed |
NCT02649348 -
Effects of Prehabilitation in Gastric Cancer Patients With Metabolic Syndrome on Perioperative Outcome
|
N/A | |
Active, not recruiting |
NCT01609309 -
Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)
|
Phase 3 | |
Completed |
NCT00375999 -
Docetaxel and Epirubicin in Advanced Gastric Cancer
|
Phase 2 | |
Completed |
NCT00382720 -
Docetaxel and Oxaliplatin in Gastric Cancer
|
Phase 2 | |
Completed |
NCT00980382 -
A Phase I/II Study of S-1 and Weekly Docetaxel for Metastatic Gastric Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05007106 -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
|
Phase 2 | |
Active, not recruiting |
NCT05602935 -
Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study
|
Phase 2 | |
Recruiting |
NCT05033392 -
PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer
|
Phase 2 | |
Completed |
NCT04539769 -
Impact of the Type of Reconstruction Methods on Diabetes Following Laparoscopic Distal Gastrectomy in Patients With Gastric Cancer and Type 2 Diabetes
|
Phase 2 | |
Active, not recruiting |
NCT02845986 -
Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02930278 -
The Effect of Preoperative Hemotologic Markers on Postoperative Long-term and Short-term Outcomes for Laparoscopic Gastrectomy
|
||
Completed |
NCT02902575 -
The Safety and Feasibility of Laparoscopic-assisted Gastrectomy for Advanced Gastric Cancer After Neoadjuvant Chemotherapy
|
N/A | |
Recruiting |
NCT04222114 -
Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis
|
Phase 3 | |
Recruiting |
NCT05068180 -
Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
|
Phase 4 | |
Not yet recruiting |
NCT05095467 -
HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction
|
Phase 2 |